Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment

International Journal of Impotence Research volume 37, pages 965–969 (2025)Cite this article

Subjects

A Comment to this article was published on 13 August 2025

Abstract

Collagenase clostridium histolyticum (CCH) was FDA-approved for treating Peyronie’s Disease (PD), demonstrating significant curvature improvement in patients during the stable phase of disease. In this retrospective cohort study, we aimed to assess the safety and effectiveness of intralesional CCH injections during the acute phase of PD. We retrospectively evaluated all men who received intralesional CCH for PD at a single academic institution between July 2017 and January 2023, focusing on patient demographics, comorbidities, pre- and post-treatment curvature, and adverse events. Patients in the acute phase had symptoms for ≤ 12 months with penile pain and/or curvature changes. A total of 100 patients treated with intralesional CCH injections for PD were included. Percent change in penile curvature was not significantly different between acute and stable phases (37.02 vs. 34.01%, p = 0.57). A total of 55 patients (76.39%) in the stable phase and 23 patients (82.14%) in the acute phase showed improvement in curvature, with no significant differences in curvature outcomes or adverse events between the two groups. This study contributes to the growing evidence that intralesional CCH treatment during the acute phase of PD is safe and effective.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016;8:61–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie’s disease in the United States: A Population-Based Study. PLoS ONE. 2016;11:e0150157.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Peyronie’s disease. J Sex Med. 2004;1:110–5.

    Article  PubMed  Google Scholar 

  4. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–3.

    Article  PubMed  Google Scholar 

  5. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.

    Article  PubMed  PubMed Central  Google Scholar 

  6. U.S. Food and Drug Administration. Center for drug evaluation and research. XIAFLEX® (collagenase clostridium histolyticum) approval letter. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125338Orig1s0061ltr.pdf.

  7. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  PubMed  Google Scholar 

  8. Hu MY, Sigalos JT, Walker DT, Li MK, Yoffe DA, Modiri N, et al. Intralesional collagenase clostridium histolyticum for acute phase Peyronie’s disease: a single-center, retrospective cohort study. Transl Androl Urol. 2022;11:1074–82.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nguyen HMT, Yousif A, Chung A, Virasoro R, Tapscott A, Ziegelmann M, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute phase Peyronie’s disease: a multi-institutional analysis. Urology. 2020;145:147–51.

    Article  PubMed  Google Scholar 

  10. Trost L, Mulhall J, Hellstrom W. Creation of a novel classification system (PTNM) for Peyronie’s disease and penile curvature using evidence-based criteria. J Urol. 2024;212:470–82.

    Article  PubMed  Google Scholar 

  11. Flores JM, Nascimento B, Punjani N, Salter CA, Bernie HL, Taniguchi H, et al. Predictors of curvature improvement in men with Peyronie’s disease treated with intralesional collagenase clostridium histolyticum. J Sex Med. 2022;19:1680–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kim HY. Statistical notes for clinical researchers: chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42:152–5.

    Article  PubMed  PubMed Central  Google Scholar 

  13. El-Khatib FM, Towe M, Yafi FA. Management of Peyronie’s disease with collagenase clostridium histolyticum in the acute phase. World J Urol. 2020;38:299–304.

    Article  PubMed  Google Scholar 

  14. Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190:627–34.

    Article  PubMed  Google Scholar 

Download references

Funding

No relevant funding for this research study.

Author information

Authors and Affiliations

  1. Department of Urology, NewYork-Presbyterian Hospital, New York, NY, USA

    Manish Kuchakulla, Hriday P. Bhambhvani, Gal Wald, Spyridon P. Basourakos, Patrick J. Lewicki, Jonathan Gal & James Kashanian

  2. Department of Urology, Weill Cornell Medical Center, New York, NY, USA

    Manish Kuchakulla, Hriday P. Bhambhvani, Gal Wald, Spyridon P. Basourakos, Patrick J. Lewicki, Jonathan Gal & James Kashanian

Authors
  1. Manish Kuchakulla
    View author publications

    Search author on:PubMed Google Scholar

  2. Hriday P. Bhambhvani
    View author publications

    Search author on:PubMed Google Scholar

  3. Gal Wald
    View author publications

    Search author on:PubMed Google Scholar

  4. Spyridon P. Basourakos
    View author publications

    Search author on:PubMed Google Scholar

  5. Patrick J. Lewicki
    View author publications

    Search author on:PubMed Google Scholar

  6. Jonathan Gal
    View author publications

    Search author on:PubMed Google Scholar

  7. James Kashanian
    View author publications

    Search author on:PubMed Google Scholar

Contributions

MK contributed to data collection, manuscript writing, and revision. HB assisted with data analysis, collection, and manuscript writing. GW helped with data analysis, manuscript writing, and revisions. SB and PL contributed to project conception, data collection, manuscript writing, and revisions. JG and JK assisted with project conception, drafting the manuscript, and providing critical revisions.

Corresponding author

Correspondence to James Kashanian.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval and consent to participate

All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by Institutional Review Board (IRB # 20-07022335) of New York Presbyterian Hospital – Weill Cornell Medical Center. Due to the retrospective nature of the study, informed consent was not required for this study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuchakulla, M., Bhambhvani, H.P., Wald, G. et al. Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment. Int J Impot Res 37, 965–969 (2025). https://doi.org/10.1038/s41443-025-01055-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41443-025-01055-0

This article is cited by

Search

Advanced search

Quick links